Skip to main content
Erschienen in: Pathology & Oncology Research 1/2010

01.03.2010

High Expression of Claudin-1 Protein in Papillary Thyroid Tumor and its Regional Lymph Node Metastasis

verfasst von: Júlia Németh, Zsuzsanna Németh, Péter Tátrai, Ilona Péter, Áron Somorácz, Attila Marcell Szász, András Kiss, Zsuzsa Schaff

Erschienen in: Pathology & Oncology Research | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Claudins, known as major contributors in the formation of the tight junction, are differentially expressed in malignant tumors as compared to the corresponding healthy tissues. Therefore, they are thought to play a role in carcinogenesis and tumor progression. Altered expression of claudin-1 has been reported in several tumor types including endometrial, papillary renal cell and colonic carcinoma, and increased claudin-1 mRNA levels have been observed in papillary thyroid carcinoma (PTC). In this study, we aimed at determining the pattern of claudin-1 expression in various types of thyroid lesions at the protein level and investigating the immunolocalization of β-catenin reported to regulate claudin-1 expression. Samples included 19 PTCs, ten cases of corresponding regional lymph node metastasis, eight papillary microcarcinomas (PMC), 17 follicular thyroid carcinomas (FTC) and 19 follicular adenomas (FA). All cases were evaluated by quantitative immunohistochemistry. Conspicuous claudin-1 immunostaining was detected in the majority of PTC/PMC primary tumors and lymph node metastases (19/27 and 9/10, respectively). On the other hand, we found weak or no claudin-1 expression in any of the FA and FTC cases or peritumoral non-malignant thyroid tissues. Our data prove that high claudin-1 protein expression is specific for PTC and its regional lymph node metastases, while we failed to verify that claudin-1 is regulated by β-catenin in thyroid tumors. Based on these results, claudin-1 may be a useful tumor marker for PTC.
Literatur
1.
Zurück zum Zitat Pacini F, Schlumberger M, Dralle H et al (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787–803CrossRefPubMed Pacini F, Schlumberger M, Dralle H et al (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787–803CrossRefPubMed
2.
Zurück zum Zitat McNicol A (2007) Pathology of thyroid tumours. Surgery 25:458–462 McNicol A (2007) Pathology of thyroid tumours. Surgery 25:458–462
3.
Zurück zum Zitat Kondo T, Ezzat S, Asa SL (2006) Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6:292–306CrossRefPubMed Kondo T, Ezzat S, Asa SL (2006) Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6:292–306CrossRefPubMed
4.
Zurück zum Zitat DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) (2004) World Health Organization classification of tumours. Pathology and genetics of tumours of endocrine organs. Thyroid and parathyroid tumours. IARC, Lyon, pp 51–123 DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) (2004) World Health Organization classification of tumours. Pathology and genetics of tumours of endocrine organs. Thyroid and parathyroid tumours. IARC, Lyon, pp 51–123
5.
Zurück zum Zitat Patricia SM (2008) Thyroid epithelial tumours. Diagn Histopathol 14:236–246CrossRef Patricia SM (2008) Thyroid epithelial tumours. Diagn Histopathol 14:236–246CrossRef
6.
Zurück zum Zitat Arif S, Blanes A, Diaz-Cano SJ (2002) Hashimoto’s thyroiditis shares features with early papillary thyroid carcinoma. Histopathol 41:357–362CrossRef Arif S, Blanes A, Diaz-Cano SJ (2002) Hashimoto’s thyroiditis shares features with early papillary thyroid carcinoma. Histopathol 41:357–362CrossRef
7.
Zurück zum Zitat Di Pasquale M, Rothstein JL, Palazzo JP (2001) Pathologic features of Hashimoto’s-associated papillary thyroid carcinomas. Hum Pathol 32:24–30CrossRefPubMed Di Pasquale M, Rothstein JL, Palazzo JP (2001) Pathologic features of Hashimoto’s-associated papillary thyroid carcinomas. Hum Pathol 32:24–30CrossRefPubMed
8.
Zurück zum Zitat Repplinger D, Bargren A, Zhang YW et al (2008) Is Hashimoto’s thyroiditis a risk factor for papillary thyroid cancer? J Surg Res 150:49–52CrossRefPubMed Repplinger D, Bargren A, Zhang YW et al (2008) Is Hashimoto’s thyroiditis a risk factor for papillary thyroid cancer? J Surg Res 150:49–52CrossRefPubMed
9.
Zurück zum Zitat González-Mariscal L, Betanzos A, Nava P et al (2003) Tight junction proteins. Prog Biophys Mol Biol 81:1–44CrossRefPubMed González-Mariscal L, Betanzos A, Nava P et al (2003) Tight junction proteins. Prog Biophys Mol Biol 81:1–44CrossRefPubMed
10.
Zurück zum Zitat Chiba H, Osanai M, Murata M et al (2008) Transmembrane proteins of tight junctions. Biochim Biophys Acta 1778:588–600CrossRefPubMed Chiba H, Osanai M, Murata M et al (2008) Transmembrane proteins of tight junctions. Biochim Biophys Acta 1778:588–600CrossRefPubMed
11.
Zurück zum Zitat Furuse M, Fujita K, Hiiragi T et al (1998) Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol 141:1539–1550CrossRefPubMed Furuse M, Fujita K, Hiiragi T et al (1998) Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol 141:1539–1550CrossRefPubMed
12.
Zurück zum Zitat Hewitt KJ, Agarwal R, Morin PJ (2006) The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer 6:186CrossRefPubMed Hewitt KJ, Agarwal R, Morin PJ (2006) The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer 6:186CrossRefPubMed
13.
Zurück zum Zitat Soini Y (2005) Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of tumours. Histopathol 46:551–560CrossRef Soini Y (2005) Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of tumours. Histopathol 46:551–560CrossRef
14.
Zurück zum Zitat Swisshelm K, Macek R, Kubbies M (2005) Role of claudins in tumorigenesis. Adv Drug Deliv Rev 57:919–928 ReviewCrossRefPubMed Swisshelm K, Macek R, Kubbies M (2005) Role of claudins in tumorigenesis. Adv Drug Deliv Rev 57:919–928 ReviewCrossRefPubMed
15.
Zurück zum Zitat Sobel G, Németh J, Kiss A et al (2006) Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma. Gynecol Oncol 103:591–598CrossRefPubMed Sobel G, Németh J, Kiss A et al (2006) Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma. Gynecol Oncol 103:591–598CrossRefPubMed
16.
Zurück zum Zitat Fritzsche FR, Oelrich B, Johannsen M et al (2008) Claudin-1 protein expression is a prognostic marker of patient survival in renal cell carcinomas. Clin Cancer Res 14:7035–7042CrossRefPubMed Fritzsche FR, Oelrich B, Johannsen M et al (2008) Claudin-1 protein expression is a prognostic marker of patient survival in renal cell carcinomas. Clin Cancer Res 14:7035–7042CrossRefPubMed
17.
Zurück zum Zitat Resnick MB, Konkin T, Routhier J et al (2005) Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study. Mod Pathol 18:511–518CrossRefPubMed Resnick MB, Konkin T, Routhier J et al (2005) Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study. Mod Pathol 18:511–518CrossRefPubMed
18.
Zurück zum Zitat Borka K, Kaliszky P, Szabó E et al (2007) Claudin expression in pancreatic endocrine tumors as compared with ductal adenocarcinomas. Virchows Arch 450:549–557CrossRefPubMed Borka K, Kaliszky P, Szabó E et al (2007) Claudin expression in pancreatic endocrine tumors as compared with ductal adenocarcinomas. Virchows Arch 450:549–557CrossRefPubMed
19.
Zurück zum Zitat Tőkés AM, Kulka J, Paku S et al (2005) Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res 7:R296–R305CrossRefPubMed Tőkés AM, Kulka J, Paku S et al (2005) Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res 7:R296–R305CrossRefPubMed
20.
Zurück zum Zitat Sobel G, Páska C, Szabó I et al (2005) Increased expression of claudins in cervical squamous intraepithelial neoplasia and invasive carcinoma. Hum Pathol 36:162–169CrossRefPubMed Sobel G, Páska C, Szabó I et al (2005) Increased expression of claudins in cervical squamous intraepithelial neoplasia and invasive carcinoma. Hum Pathol 36:162–169CrossRefPubMed
21.
Zurück zum Zitat Krause G, Winkler L, Mueller SL et al (2008) Structure and function of claudins. Biochim Biophys Acta 1778:631–645PubMed Krause G, Winkler L, Mueller SL et al (2008) Structure and function of claudins. Biochim Biophys Acta 1778:631–645PubMed
22.
Zurück zum Zitat Kominsky SL (2006) Claudins: emerging targets for cancer therapy. Expert Rev Mol Med 8:1–11CrossRefPubMed Kominsky SL (2006) Claudins: emerging targets for cancer therapy. Expert Rev Mol Med 8:1–11CrossRefPubMed
23.
Zurück zum Zitat Morin PJ (2005) Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 65:9603–9606CrossRefPubMed Morin PJ (2005) Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 65:9603–9606CrossRefPubMed
24.
Zurück zum Zitat Tzelepi VN, Tsamandas AC, Vlotinou HD et al (2008) Tight junctions in thyroid carcinogenesis: diverse expression of claudin-1, claudin-4, claudin-7 and occludin in thyroid neoplasms. Mod Pathol 21:22–30CrossRefPubMed Tzelepi VN, Tsamandas AC, Vlotinou HD et al (2008) Tight junctions in thyroid carcinogenesis: diverse expression of claudin-1, claudin-4, claudin-7 and occludin in thyroid neoplasms. Mod Pathol 21:22–30CrossRefPubMed
25.
Zurück zum Zitat Hucz J, Kowalska M, Jarząb M et al (2006) Gene expression of metalloproteinase 11, claudin 1 and selected adhesion related genes in papillary thyroid cancer. Endokrynol Pol 57(SupplA):18–25PubMed Hucz J, Kowalska M, Jarząb M et al (2006) Gene expression of metalloproteinase 11, claudin 1 and selected adhesion related genes in papillary thyroid cancer. Endokrynol Pol 57(SupplA):18–25PubMed
26.
Zurück zum Zitat Fluge Ø, Bruland O, Akslen LA et al (2006) Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid 16:161–175CrossRefPubMed Fluge Ø, Bruland O, Akslen LA et al (2006) Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid 16:161–175CrossRefPubMed
27.
Zurück zum Zitat Miwa N, Furuse M, Tsukita S et al (2001) Involvement of claudin-1 in the β-catenin/Tcf signaling pathway and its frequent pregulation in human colorectal cancers. Oncol Res 12:469–476PubMed Miwa N, Furuse M, Tsukita S et al (2001) Involvement of claudin-1 in the β-catenin/Tcf signaling pathway and its frequent pregulation in human colorectal cancers. Oncol Res 12:469–476PubMed
28.
Zurück zum Zitat Halász J, Holczbauer Á, Cs P, Kovács M, Benyó G, Verebély T, Zs S, Kiss A (2006) Claudin-1 and claudin-2 differentiate fetal and embryonal components in human hepatoblastoma. Human Pathol 37:555–561CrossRef Halász J, Holczbauer Á, Cs P, Kovács M, Benyó G, Verebély T, Zs S, Kiss A (2006) Claudin-1 and claudin-2 differentiate fetal and embryonal components in human hepatoblastoma. Human Pathol 37:555–561CrossRef
29.
Zurück zum Zitat Liu YY, Morreau H, Kievit J et al (2008) Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. Eur J Endocrinol 158:375–384CrossRefPubMed Liu YY, Morreau H, Kievit J et al (2008) Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. Eur J Endocrinol 158:375–384CrossRefPubMed
30.
Zurück zum Zitat Dhawan P, Singh AB, Deane NG et al (2005) Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest 115:1765–1776CrossRefPubMed Dhawan P, Singh AB, Deane NG et al (2005) Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest 115:1765–1776CrossRefPubMed
31.
Zurück zum Zitat Wu YL, Zhang S, Wang GR et al (2008) Expression transformation of claudin-1 in the process of gastric adenocarcinoma invasion. World J Gastroenterol 14:4943–4948CrossRefPubMed Wu YL, Zhang S, Wang GR et al (2008) Expression transformation of claudin-1 in the process of gastric adenocarcinoma invasion. World J Gastroenterol 14:4943–4948CrossRefPubMed
32.
Zurück zum Zitat Kondo J, Sato F, Kusumi T et al (2008) Claudin-1 expression is induced by tumor necrosis factor-alpha in human pancreatic cancer cells. Int J Mol Med 22:645–649PubMed Kondo J, Sato F, Kusumi T et al (2008) Claudin-1 expression is induced by tumor necrosis factor-alpha in human pancreatic cancer cells. Int J Mol Med 22:645–649PubMed
33.
Zurück zum Zitat Chao YC, Pan SH, Yang SC et al (2009) Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma. Am J Respir Crit Care Med 179:123–33CrossRefPubMed Chao YC, Pan SH, Yang SC et al (2009) Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma. Am J Respir Crit Care Med 179:123–33CrossRefPubMed
34.
Zurück zum Zitat Aldred MA, Huang Y, Liyanarachchi S et al (2004) Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol 22:3531–3539CrossRefPubMed Aldred MA, Huang Y, Liyanarachchi S et al (2004) Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol 22:3531–3539CrossRefPubMed
35.
Zurück zum Zitat Firestein R, Bass AJ, Kim SY et al (2008) CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature 455:547–551CrossRefPubMed Firestein R, Bass AJ, Kim SY et al (2008) CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature 455:547–551CrossRefPubMed
36.
Zurück zum Zitat Elzagheid A, Buhmeida A, Korkeila E et al (2008) Nuclear beta-catenin expression as a prognostic factor in advanced colorectal carcinoma. World J Gastroenterol 14:3866–3871CrossRefPubMed Elzagheid A, Buhmeida A, Korkeila E et al (2008) Nuclear beta-catenin expression as a prognostic factor in advanced colorectal carcinoma. World J Gastroenterol 14:3866–3871CrossRefPubMed
37.
Zurück zum Zitat Ishigaki K, Namba H, Nakashima M et al (2002) Aberrant localization of beta-catenin correlates with overexpression of its target gene in human papillary thyroid cancer. J Clin Endocrinol Metab 87:3433–40CrossRefPubMed Ishigaki K, Namba H, Nakashima M et al (2002) Aberrant localization of beta-catenin correlates with overexpression of its target gene in human papillary thyroid cancer. J Clin Endocrinol Metab 87:3433–40CrossRefPubMed
38.
Zurück zum Zitat Wang Z, Qiu S, Eltorky MA et al (2007) Histopathologic and immunohistochemical characterization of a primary papillary thyroid carcinoma in the lateral cervical lymph node. Exp Mol Pathol 82:91–4CrossRefPubMed Wang Z, Qiu S, Eltorky MA et al (2007) Histopathologic and immunohistochemical characterization of a primary papillary thyroid carcinoma in the lateral cervical lymph node. Exp Mol Pathol 82:91–4CrossRefPubMed
39.
Zurück zum Zitat Nikiforov YE (2008) Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 21(Suppl 2):S37–43CrossRefPubMed Nikiforov YE (2008) Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 21(Suppl 2):S37–43CrossRefPubMed
Metadaten
Titel
High Expression of Claudin-1 Protein in Papillary Thyroid Tumor and its Regional Lymph Node Metastasis
verfasst von
Júlia Németh
Zsuzsanna Németh
Péter Tátrai
Ilona Péter
Áron Somorácz
Attila Marcell Szász
András Kiss
Zsuzsa Schaff
Publikationsdatum
01.03.2010
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 1/2010
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-009-9182-9

Weitere Artikel der Ausgabe 1/2010

Pathology & Oncology Research 1/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.